Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29277042 | 0.98 | HTR3A (0.50) | HTR3A | |
| SCHEMBL14734253 | 0.88 | HTR3A (0.41) | HTR3A | |
| Hydrochloric Acid SCHEMBL30758569 | 0.86 | HTR3A (0.40) | HTR3A | |
| SCHEMBL1739269 | 0.84 | CHRNB2 (0.39) | HTR3A | |
| SCHEMBL2636887 | 0.81 | MPO (0.41) | HTR3A | |
| SCHEMBL2636647 | 0.81 | HTR3A (0.39) | HTR3A | |
| SCHEMBL2636898 | 0.81 | HTR3A (0.39) | HTR3A | |
| SCHEMBL20387698 | 0.81 | HTR3A (0.39) | HTR3A | |
| SCHEMBL31084105 | 0.79 | SMN1; SMN2 (0.38) | HTR3A | |
| SCHEMBL1741786 | 0.78 | HTR3A (0.42) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023241684-A1 | PDE4B INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-12-21 | — | — | WO | disclosed |
| CN-117247395-A | PDE4B inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-9163012-B2 | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2438043-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2010141424-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | HTR3A 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.